The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,344.00
Bid: 12,342.00
Ask: 12,346.00
Change: 226.00 (1.86%)
Spread: 4.00 (0.032%)
Open: 12,244.00
High: 12,344.00
Low: 12,228.00
Prev. Close: 12,118.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

CORRECTED-After 4.2 million COVID-19 cases in November, U.S. pins hope on vaccine

Tue, 01st Dec 2020 12:54

(Corrects details of vaccine approval procedure, third
paragraph)

WASHINGTON, Dec 1 (Reuters) - The United States entered the
final month of the year hoping that promising vaccine candidates
will soon be approved to halt the rapidly spreading novel
coronavirus after 4.2 million new cases were reported in
November.

The new COVID-19 cases were more than double the previous
monthly record set in October, as large numbers of Americans
still refuse to refuse to wear masks and continue to gather in
holiday crowds, against the recommendation of experts.

With outgoing President Donald Trump's coronavirus strategy
relying heavily on a vaccine, a Food and Drug Administration
panel of outside advisers will meet on Dec. 10 to discuss
whether to recommend the FDA authorize emergency use of a
vaccine developed by Pfizer Inc.

A second candidate from Moderna Inc could follow a
week later, officials have said, raising hopes that Americans
could start receiving inoculations before the end the year,
although widespread vaccinations could take months.

Other global pharmaceuticals including AstraZeneca PLC
and Johnson & Johnson also have vaccines in the
works, leading a member of the Trump administration's "Operation
Warp Speed" program to predict the country could be vaccinated
by June.

"One hundred percent of the Americans that want the vaccine
will have the vaccine by (June). We will have over 300 million
doses available to the American public well before then," Paul
Ostrowski, the vaccine program's director of supply, production
and distribution, told MSNBC television on Monday.

In the meantime, leading health officials are pleading with
Americans to follow their recommendations and help arrest a
pandemic that killed more than 36,000 people in November,
pushing hospitalizations to a record high of nearly 93,000 on
Sunday, according to a Reuters tally.

The widespread impact of the pandemic has led
Merriam-Webster to choose "pandemic" as the Word of the Year
after it racked up the most online dictionary lookups of any
word.

"Sometimes a single word defines an era, and it's fitting
that in this exceptional - and exceptionally difficult - year, a
single word came immediately to the fore," the dictionary
publisher said.

With more than 10,000 people dying and 1.1 million
contracting the novel coronavirus in the week ended Sunday,
Trump has remained focused on overturning the results of the
Nov. 3 election won by President-elect Joe Biden, denying Trump
a second term.

Biden has pledged to make combating the coronavirus his top
priority upon taking office on Jan. 20, saying he will rely on
the best scientific evidence.

In the absence of a federal blueprint to curb the spread of
the virus, states are issuing new or revamped restrictions on
businesses and social life.

California's governor said he may renew a stay-at-home order
in the coming days, warning that ICU admissions are on track to
exceed statewide capacity by mid-December unless public health
policies and social behavior change.

"The red flags are flying," Governor Gavin Newsom told
reporters in an online briefing. "If these trends continue,
we're going to have to take much more dramatic, arguably
drastic, action."

(Reporting by Reuters staff; Writing by Daniel Trotta; Editing
by Bernadette Baum)

More News
27 Nov 2023 16:12

London close: Stocks start week in subdued state

(Sharecast News) - London's financial markets saw a somewhat subdued performance on Monday, as concerns regarding the Chinese economy cast a shadow over investor sentiment.

Read more
27 Nov 2023 09:20

LONDON BROKER RATINGS: Peel, Numis up Rightmove; Goldman cuts Entain

(Alliance News) - The following London-listed shares received analyst recommendations Monday morning and Friday:

Read more
23 Nov 2023 18:41

IN BRIEF: AstraZeneca Chair Demare buys shares for over GBP200,000

AstraZeneca PLC - Cambridge-based pharmaceutical company - Chair Michel Demare buys 2,000 shares in total on Wednesday and Tuesday. Buys 1,000 shares for GBP101.05 each on Tuesday and 1,000 shares for GBP101.70 each on Thursday, for a total of GBP202,752.

Read more
20 Nov 2023 10:49

AstraZeneca launches new life sciences tech innovation firm Evinova

(Alliance News) - AstraZeneca PLC on Monday launched Evinova, a new health technology business focused on accelerating innovation across the life sciences sector, delivery of clinical trials and better health outcomes.

Read more
17 Nov 2023 15:20

London close: Stocks higher despite weaker retail sales data

(Sharecast News) - London's stock markets finished in a positive state on Friday despite weaker-than-expected UK retail sales figures.

Read more
17 Nov 2023 12:00

LONDON MARKET MIDDAY: Stocks shrug off downbeat UK retail sales

(Alliance News) - Stock prices in London were up at midday on Friday, as a week of favourable data as far as inflation goes gave investors a reason to overlook disappointing UK retail sales figures.

Read more
17 Nov 2023 09:03

LONDON MARKET OPEN: Stocks up despite UK retail sales growth miss

(Alliance News) - Stock prices in London opened higher on Friday, despite weaker-than-expected October retail sales figures for the UK.

Read more
17 Nov 2023 08:31

TOP NEWS: US approves AstraZeneca's Truqap for form of breast cancer

(Alliance News) - AstraZeneca PLC on Friday said that the US Food & Drug Administration approved its drug Truqap in combination with Faslodex to treat patients with an advanced form of breast cancer.

Read more
17 Nov 2023 07:58

LONDON BRIEFING: UK retail sales fall; AstraZeneca gets US approval

(Alliance News) - Stock prices in London are still set to open higher on Friday, despite October retail sales figures for the UK disappointing shortly before the opening bell.

Read more
17 Nov 2023 07:16

AstraZeneca gets US approval for breast cancer treatment

(Sharecast News) - AstraZeneca's 'Truqap', or capivasertib, in combination with 'Faslodex', or fulvestrant, has secured approval from the US Food and Drug Administration (FDA) for specific breast cancer treatments, the company announced on Friday.

Read more
14 Nov 2023 10:51

TOP NEWS: AstraZeneca Imfinzi fails to meet endpoint in cancer trial

(Alliance News) - AstraZeneca PLC on Tuesday said the Pacific-2 phase III trial for Imfinzi as an early treatment lung cancer immunotherapy treatment administered with chemoradiotherapy, did not meet its primary endpoint.

Read more
14 Nov 2023 09:22

AstraZeneca's latest lung cancer trial fails its primary endpoint

(Sharecast News) - AstraZeneca announced on Tuesday that its 'PACIFIC-2' phase three trial for Imfinzi, or durvalumab, concurrently administered with chemoradiotherapy (CRT), did not achieve its primary endpoint of progression-free survival compared to CRT alone.

Read more
13 Nov 2023 09:45

LONDON BROKER RATINGS: Diageo gets price target cuts; JPMorgan ups M&G

(Alliance News) - The following London-listed shares received analyst recommendations Monday morning:

Read more
9 Nov 2023 15:02

London close: Stocks gain as investors await Powell speech

(Sharecast News) - London's stock markets were buoyant at the close of trading on Thursday, influenced by Chinese inflation data, a substantial influx of corporate news, and a speech from the Fed chair later in the global day.

Read more
9 Nov 2023 12:06

LONDON MARKET MIDDAY: FTSE up despite higher for longer US rates fear

(Alliance News) - European equities were on the up on Thursday, despite lingering US interest rate worries and poor China data.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.